Multiple System Atrophy
Speech, language, and swallowing decline in (MSA) are directly linked to disease severity and patient function, serving as sensitive markers of progression. Redenlab’s digital assessments offer quantifiable, low-burden endpoints for tracking bulbar and cognitive-motor changes in clinical trials.
Why speech matters in Multiple System Atrophy
MSA is a rare, rapidly progressive neurodegenerative disorder with hallmark features of dysarthria and dysphagia affecting over 90% of individuals as the disease advances. These impairments significantly impact communication, nutritional safety, and independence, contributing to social withdrawal and reduced quality of life. The progression of speech and swallowing symptoms can be difficult to track with traditional assessments. Redenlab provides objective, high-frequency digital monitoring tools that capture subtle changes in bulbar and cognitive-motor function to support clinical decision-making and treatment evaluation.
Enhanced speech and swallowing analysis for MSA trials
Bulbar-focussed digital endpoints
Purpose-built tools for capturing dysarthria and dysphagia, which are early and prominent features in MSA.
Sensitive to MSA subtypes
Algorithms tailored for parkinsonian (MSA-P) and cerebellar (MSA-C) presentations, capturing speech variability and motor control.
Regulatory-aligned speech biomarkers
Objective, repeatable measures to support longitudinal tracking and therapeutic efficacy for MSA.
Validated across rare disease cohorts
Proven implementation in low-prevalence neurodegenerative populations with remote, scalable deployment.
Real-world function and quality of life insight
Speech and swallowing outcomes aligned with patient-centred metrics such as intelligibility, communication burden and nutritional risk.
Redenlab’s MSA experience
No. of Sites: 65
No. of Patients assessed: 165
No. of Languages: 10
Redenlab has supported a large industry sponsored Phase II multi-language, multi-national clinical trial in MSA for the past few years. Lessons learned from this pivotal trial provide invaluable experience in future RCTs in this complex condition.
